Table 1 Patients and transplantation characteristics
Characteristics | HID | MSD | MUD | P-value |
|---|---|---|---|---|
N = 184 | N = 39 | N = 36 | ||
Age | 0.406 | |||
Below sixty | 132 (72%) | 32 (82%) | 27 (75%) | |
Over sixty | 52 (28%) | 7 (18%) | 9 (25%) | |
Sex | 0.503 | |||
Female | 59 (32%) | 12 (31%) | 15 (42%) | |
Male | 125 (68%) | 27 (69%) | 21 (58%) | |
Diagnosis | 0.089 | |||
AML | 126 (68%) | 20 (51%) | 21 (58%) | |
MDS | 58 (31%) | 19 (49%) | 15 (42%) | |
ECOG | 0.744 | |||
0–1 | 150 (81%) | 33 (85%) | 30 (83%) | |
2 | 27 (15%) | 4 (10%) | 6 (17%) | |
3–4 | 7 (4%) | 2 (5%) | 0 (0%) | |
HCT-CI | 0.778 | |||
0–1 | 125 (68%) | 27 (69%) | 27 (75%) | |
2–3 | 48 (26%) | 10 (26%) | 6 (17%) | |
4–6 | 11 (6%) | 2 (5%) | 3 (8%) | |
TCI | 0.481 | |||
< 4 | 59 (32%) | 11 (28%) | 8 (22%) | |
≥ 4 | 125 (68%) | 28 (72%) | 28 (78%) | |
Refractory or relapsed | 0.360 | |||
No | 100 (54%) | 25 (64%) | 23 (64%) | |
Yes | 84 (46%) | 14 (36%) | 13 (36%) | |
Cytogenetic evaluation† | 0.162 | |||
Favourable or intermediate risk | 117 (64%) | 22 (56%) | 17 (47%) | |
Adverse risk | 67 (36%) | 17 (44%) | 19 (53%) | |
CR1 | 0.451 | |||
Not | 110 (60%) | 26 (67%) | 25 (69%) | |
Yes | 74 (40%) | 13 (33%) | 11 (31%) | |
Donor to recipient | 0.017* | |||
Others | 144 (78%) | 34 (87%) | 35 (97%) | |
Female to male | 40 (22%) | 5 (13%) | 1 (3%) | |
Anti-HLA | 0.683 | |||
Negative | 157 (85%) | 34 (87%) | 33 (92%) | |
Positive | 27 (15%) | 5 (13%) | 3 (8%) | |
Graft source | < 0.001* | |||
PB | 104 (56%) | 30 (77%) | 35 (97%) | |
BM | 5 (3%) | 0 (0%) | 0 (0%) | |
PB + BM | 75 (41%) | 9 (23%) | 1 (3%) | |
ABO blood type | 0.026* | |||
Matched | 89 (48%) | 26 (67%) | 13 (36%) | |
Not matched | 95 (52%) | 13 (33%) | 23 (64%) | |
MNC (median) | 10.5 | 10.2 | 8.3 | 0.010* |
CD34+ cells(median) | 1.9 | 2.0 | 1.4 | < 0.001* |